🔎 Trials Near Me

홈 › 요로상피(이행상피)암 › 텍사스

텍사스의 요로상피(이행상피)암 임상 시험

요로상피(이행상피)암 관련 연구 39개가 텍사스 내 여러 지역에서 참여자를 모집하고 있습니다.

텍사스의 도시

공식 연구 텍스트(영어)

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

  • Houston Methodist San Jacinto Hospital, Baytown
  • Houston Methodist Cypress Hospital, Cypress
  • Parkland Memorial Hospital, Dallas
  • 외 10개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT06524544

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

  • Texas Oncology, Austin
  • Texas Oncology - Northeast Texas, Tyler
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT07566156

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  • UT Southwestern Simmons Cancer Center - RedBird, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
  • UT Southwestern/Simmons Cancer Center-Fort Worth, Fort Worth
  • 외 1개
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT03866382

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto

  • UT Southwestern Medical Center, Dallas
  • The University of Texas M.D. Anderson Cancer Center, Houston
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT05874921

DBC-664 in Adult Patients With Solid Tumors

  • START San Antonio, San Antonio
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT07705035

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

  • Texas Oncology - Central/South Texas, Austin
  • Texas Oncology - Central/South Texas, Austin
  • Texas Oncology - Central/South Texas, Austin
  • 외 13개
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT07421700

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

  • START Dallas Fort Worth, Fort Worth
  • MD Anderson, Houston
  • NEXT Oncology Houston, Houston
  • 외 1개
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT07277413

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

  • Baylor, Scott and White Research Institute, Dallas
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 24. 업데이트됨 · NCT06047379

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  • USO-Texas Oncology-Central/South Texas, Austin
  • World Research Link, Baytown
  • Parkland Health and Hospital System, Dallas
  • 외 5개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07218380

Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy

  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 21. 업데이트됨 · NCT06439836

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

  • Start - Dfw, Fort Worth
  • Oncology Consultants, Houston
  • START - San Antonio, San Antonio
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 10. 업데이트됨 · NCT06293898

A Study of GEN1106 in Participants With Solid Tumors

  • South Texas Accelerated Research Therapeutics, San Antonio
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 10. 업데이트됨 · NCT07416123

A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

  • The University of Texas MD Anderson Cancer Center - Conroe, Conroe
  • University of Texas MD Anderson Cancer Center, Houston
  • The University of Texas, MD Anderson Cancer Center - West Houston, Houston
  • 외 3개
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 4. 업데이트됨 · NCT07090499

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

  • UPNT Research Institute, LLC, Arlington
  • Texas Urology Specialists-Austin, Austin
  • Houston Metro Urology (HMU) - Southwest Location, Houston
  • 외 3개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 3. 업데이트됨 · NCT06774131

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

  • START San Antonio, San Antonio
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 27. 업데이트됨 · NCT06582017

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

  • Research Site, Dallas
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 8. 20. 업데이트됨 · NCT07129993

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

  • NEXT Oncology, Austin, Austin
  • NEXT Oncology, San Antonio, San Antonio
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 18. 업데이트됨 · NCT06966024

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

  • Houston Methodist Hospital, Houston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 17. 업데이트됨 · NCT04895709

A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

  • Clinical Trial Site, San Antonio
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 6. 업데이트됨 · NCT07749586

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  • Texas Oncology - West Texas, Amarillo
  • Texas Oncology, P.A., Dallas
  • Texas Oncology Gulf Coast, Pearland
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 5. 업데이트됨 · NCT06330064

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

  • Exelixis Clinical Site #46, Austin
  • Exelixis Clinical Site #111, Dallas
  • Exelixis Clinical Site #89, Dallas
  • 외 3개
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 5. 업데이트됨 · NCT05176483

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

  • NEXT Austin, Austin
  • START Center for Clinical Research, Fort Worth
  • University of Texas MD Anderson Cancer Center, Houston
  • 외 1개
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 3. 업데이트됨 · NCT06270706

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

  • The University of Texas Health Science Center at Tyler, Tyler
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 7. 29. 업데이트됨 · NCT04198766

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

  • Baylor Scott and White Research Institute, Dallas
  • The University of Texas MD Anderson Cancer Center, Houston
  • Baylor Scott & White Medical Center - Temple, Temple
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 7. 22. 업데이트됨 · NCT04879329

An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

  • Research Site, Dallas
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 7. 22. 업데이트됨 · NCT07720284

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

  • Texas Oncology - DFW, Dallas
  • MD Anderson Cancer Center, Houston
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 7. 10. 업데이트됨 · NCT06695845

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

  • MD Anderson Cancer Center, Houston
  • Next Oncology-Oncology, San Antonio
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 7. 2. 업데이트됨 · NCT07169734

Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.

  • Austin Urology Institute, Austin
  • UT Southwestern Medical Center, Dallas
피험자 모집 중
18세 ~ 88세 · 모든 성별 · 2026. 7. 2. 업데이트됨 · NCT06394869

Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platform for Detection and Surveillance of Bladder Cancer

  • UT Southwestern Medical Center, Dallas
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 6. 29. 업데이트됨 · NCT07673016

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

  • MDACC, Houston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 6. 18. 업데이트됨 · NCT07484022

A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

  • University of Texas MD Anderson Cancer Center, Houston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 5. 15. 업데이트됨 · NCT04969835

Bladder Cancer Screening Trial

  • University of Texas Southwestern Medical Center, Dallas
피험자 모집 중
50세 이상 · 모든 성별 · 2026. 5. 1. 업데이트됨 · NCT05646485

Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial

  • M D Anderson Cancer Center, Houston
피험자 모집 중
18세 이상 · 모든 성별 · 2026. 4. 15. 업데이트됨 · NCT04693377

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

  • NEXT Oncology, Austin, TX 78758
  • NEXT Oncology, San Antonio
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 4. 2. 업데이트됨 · NCT06451497

An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy

  • University of Texas Southwestern Medical Center, Dallas
피험자 모집 중건강한 지원자 환영
18세 이상 · 모든 성별 · 2026. 1. 28. 업데이트됨 · NCT04623502

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

  • Dren Investigational Site, Austin
  • Dren Investigational Site, Dallas
  • Dren Investigational Site, San Antonio
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 1. 7. 업데이트됨 · NCT06999187

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

  • The University of Texas MD Anderson Cancer Center, Houston
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2025. 12. 11. 업데이트됨 · NCT06943521

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Dallas
  • Massive Bio SYNERGY-AI site, Houston
  • Massive Bio SYNERGY-AI site, Temple
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2025. 10. 28. 업데이트됨 · NCT03452774

A Study of NX-1607 in Adults With Advanced Malignancies

  • MD Anderson Cancer Center, Houston
피험자 모집 중1상
18세 이상 · 모든 성별 · 2025. 9. 9. 업데이트됨 · NCT05107674

ClinicalTrials.gov 출처, 2026. 10. 1. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.